EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. - Test2 - elhamkhani - TriplyDB

EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.

EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.

http://www.wikidata.org/entity/Q30538848

about

Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells BRCA1 is a negative modulator of the PRC2 complex One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling The Functional Role of PRC2 in Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) - Mechanisms and Opportunities The Androgen Receptor Bridges Stem Cell-Associated Signaling Nodes in Prostate Stem Cells Targeting EZH2 in cancer EZH2 in normal hematopoiesis and hematological malignancies Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications The mutational landscape of prostate cancer Emerging players in prostate cancer: long non-coding RNAs Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer Recent progress toward epigenetic therapies: the example of mixed lineage leukemia Retinoids induce stem cell differentiation via epigenetic changes Chromatin targeting drugs in cancer and immunity Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET Domain Epigenetic modulators as therapeutic targets in prostate cancer Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy EZH2 in Bladder Cancer, a Promising Therapeutic Target Diverse involvement of EZH2 in cancer epigenetics SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 The methyltransferases enhancer of zeste homolog (EZH) 1 and EZH2 control hepatocyte homeostasis and regeneration Terminal epidermal differentiation is regulated by the interaction of Fra-2/AP-1 with Ezh2 and ERK1/2 CR Cistrome: a ChIP-Seq database for chromatin regulators and histone modification linkages in human and mouse N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer Prostate cancer epigenetics and its clinical implications Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro Occupying Chromatin: Polycomb Mechanisms for Getting to Genomic Targets, Stopping Transcriptional Traffic, and Staying Put Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns.EZH2: not EZHY (easy) to deal.HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination.Co-occurring protein phosphorylation are functionally associated.PAF and EZH2 induce Wnt/β-catenin signaling hyperactivation.Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice Depletion of polycomb repressive complex 2 core component EED impairs fetal hematopoiesis.Ezh2 regulates transcriptional and posttranslational expression of T-bet and promotes Th1 cell responses mediating aplastic anemia in mice.Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.Functional and therapeutic significance of EZH2 in urological cancers Androgen receptor functions in prostate cancer development and progression Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression.

P2860

Q24293124-344A6A84-F689-49A9-A55E-70EDE8182A71 Q24339430-B484AB9E-5E7F-42CF-9205-C30AA59D0F55 Q26740548-C8072238-88F5-489F-940C-89C0682A90FA Q26744506-3AEA07B2-29DA-49F4-A2B4-8FEDA837448D Q26765892-2F08706B-297F-4893-B638-2987A0BC629A Q26769027-55AE1368-EDD0-4B54-AB50-FC0E2D5D0205 Q26779821-DF3A736B-B6A3-4E12-A176-354F46F96025 Q26801380-CD84D5F5-514A-424A-A7D2-3D5A55A703D6 Q26851631-932E1426-0B3B-4DE3-9913-F423290B9979 Q26853712-5F95D987-C550-4BC7-A49B-A1926493BCE5 Q26858922-447564E7-5889-411B-B2CD-B5B2456EAAB9 Q26863577-CC8978B2-D3F6-4909-BC80-3A4F6BC267C5 Q26866234-2120D5CC-A0EA-4CE6-87E0-2A5D6B9C5F71 Q26999888-DC477C57-2D0A-4C25-9082-087AECB167BC Q27681087-ED48AA2C-DBD6-420A-88B0-386D3458D1CC Q28071912-2057C7BE-CEF5-4A6B-8BF1-77A64485CCCA Q28073470-FD049BC8-3005-4C1F-BEA9-E0C35C08308A Q28082054-FADF49B8-DE31-4BDD-B1C3-2FA3C8E2C625 Q28084911-DB5DEE8C-5421-469D-99FA-D7A7E72651B8 Q28269618-B3972C25-78D9-425A-9088-06CD65C088F0 Q28509576-1D778D76-E6C0-4270-A714-7C218FCB92EA Q28589232-65CBF3BA-9688-408E-830C-F8DC77E32061 Q28660713-52B56BC8-030F-4A08-9035-37EFE1EB4BAC Q28771715-6F5A1596-4AE8-4E0B-AB7C-756E68ACC676 Q28829460-D2053556-8610-4925-BCE9-7D7C969F6F63 Q29147503-23B4B2A8-19FD-4D23-A009-3EB90361F92A Q29301233-B88CD88A-22E4-442C-BECC-04D2D10FC031 Q33568125-B8A83BFB-A0D3-465F-9DFF-1CCD9AA1DD56 Q33610902-39198E07-25AA-4FBC-B851-148397C439B4 Q33623369-DF8A3330-85DD-4ACF-AC54-007527572E05 Q33626131-9578050B-C31F-45BA-AC7D-10E429DEB502 Q33688357-87CE4B21-AE01-4F2E-9C2C-AECF38EE5F95 Q33693019-2F34E945-E2A7-4476-A4F6-C2A6A97A3150 Q33707337-8AA6B442-713A-408F-B220-6040DB2DFB76 Q33815911-1B345D30-877F-455C-B59D-D27D08CB04C4 Q33824617-0628EE35-B38D-4502-BB51-22566D714214 Q33914216-2CB8680B-4E32-4DDA-9119-C69AEE07D7CC Q33914244-690B359A-9B8B-4BFF-A3C4-73FC9096E09A Q33922393-F6A9C86A-8549-4C7E-B3A7-BE6E617BB4B0 Q34000446-8BE04D7A-E2BD-40C7-997D-204C9D3F832D

P2860

EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.

http://www.wikidata.org/entity/Q30538848

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

EZH2 oncogenic activity in cas ...... cells is Polycomb-independent.

@ast

EZH2 oncogenic activity in cas ...... cells is Polycomb-independent.

@en

type

label

EZH2 oncogenic activity in cas ...... cells is Polycomb-independent.

@ast

EZH2 oncogenic activity in cas ...... cells is Polycomb-independent.

@en

prefLabel

EZH2 oncogenic activity in cas ...... cells is Polycomb-independent.

@ast

EZH2 oncogenic activity in cas ...... cells is Polycomb-independent.

@en

P1433

Q30538848-BC8DB0A0-06FD-44E7-8C1F-B3DEAE96FA12

P1476

Q30538848-8197EA08-3A09-4CBF-A4A7-0E406D89DB4B

P2093

Q30538848-33C25CFA-0E6A-4397-BCED-FE898DA5F9C7

Q30538848-3E75BB22-97C4-419D-A062-378B5B002BA9

Q30538848-53351747-7052-4B63-B3D9-33FECCD8B798

Q30538848-5FD53D0D-089F-47DD-AEF6-D23920AD10D8

Q30538848-6763B901-9251-41C3-9A5D-CC223340A749

Q30538848-6A0C209D-1518-4D9A-BCAB-82B0A0185533

Q30538848-6F36D01E-D657-41D4-BB65-F3B476CD18F6

Q30538848-77FC528E-17EA-4A16-A27E-7639A61AF7EF

Q30538848-93AFB3D8-0D0D-4152-8BD2-EBED4658F8A7

Q30538848-9689E729-B611-4803-9887-9912B206EBEB

P2860

Q30538848-0550ED76-DF1B-4573-A89D-F94A083001CD

Q30538848-15A11430-631B-41AA-9047-1C0E752BADAF

Q30538848-20BD156E-7808-45FA-BF18-3F758BDF24DA

Q30538848-2A3601E4-AEE4-4753-BF5D-547A584F9E47

Q30538848-2D76BEF7-EC6F-4B0E-AEB9-EFF1F4D3B732

Q30538848-3128CBA9-B86B-4373-AA56-4B887BCAE245

Q30538848-33D3BCC6-9DEE-453B-85F0-66CC12B1917B

Q30538848-35EE7FB1-6648-450F-A72D-C419077E9FF1

Q30538848-39B1CF00-90AB-4E75-865D-56CE47B8E6B3

Q30538848-44FF2BE8-7BAF-4777-A681-475C2A177F37

P304

Q30538848-C014D5DD-3615-4BFB-8333-5A05E4099D54

P31

Q30538848-63D5B44F-D504-4100-AC36-95396CA33613

P356

Q30538848-CB75AFC8-7BAF-4FB4-8CF4-351C1D3110C6

P407

Q30538848-847DF526-8485-43D4-9D75-2B7BE67FC66D

P433

Q30538848-BF03C636-2623-46AB-9555-7C3036A624A0

P478

Q30538848-C328F30C-0502-4D3A-B252-611F85242E42

P50

Q30538848-2224B2A2-7896-44BA-9466-979771A9A7E6

Q30538848-4E40BE34-2565-4492-80D0-84F08DE5473C

Q30538848-9C19AFBE-57B0-4B49-90C3-8EA439D49BC1

Q30538848-B2C406E7-45CE-4894-87D2-17E5F1032C64

Q30538848-C825FB7F-8802-4A86-A81D-71D4B3901610

Q30538848-CE2E5234-8EF9-4E2C-861F-F63A22C8CAA5

Q30538848-D3597B0D-7E85-4D60-B75C-C1326DF5117B

P577

Q30538848-8C595D22-62D8-4209-87B5-38DF28395EAF

P5875

Q30538848-A10A1FC9-D299-4542-B77F-72433E0474F1

P698

Q30538848-FC9759AF-5EF2-4635-99EE-E013B1B7C113

P932

Q30538848-C984B30A-8861-4574-85F7-B35B97E6E7D6

P356

SCIENCE.1227604

P1433

P1476

EZH2 oncogenic activity in cas ...... cells is Polycomb-independent.

@en

P2093

Anna C Groner

http://www.w3.org/2001/XMLSchema#string

Colm Morrissey

http://www.w3.org/2001/XMLSchema#string

Cristina Magi-Galluzzi

http://www.w3.org/2001/XMLSchema#string

Edward C Stack

http://www.w3.org/2001/XMLSchema#string

Han Xu

http://www.w3.org/2001/XMLSchema#string

James E Thornton

http://www.w3.org/2001/XMLSchema#string

Kexin Xu

http://www.w3.org/2001/XMLSchema#string

Laura Cato

http://www.w3.org/2001/XMLSchema#string

Richard I Gregory

http://www.w3.org/2001/XMLSchema#string

Robert L Vessella

http://www.w3.org/2001/XMLSchema#string

P2860

Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2

Gene expression profiling predicts clinical outcome of prostate cancer

Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA

Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.

Role of histone H3 lysine 27 methylation in Polycomb-group silencing

PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth

Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3

Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3

The polycomb group protein EZH2 is involved in progression of prostate cancer

P304

1465-1469

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.1227604

http://www.w3.org/2001/XMLSchema#string

P407

P433

6113

http://www.w3.org/2001/XMLSchema#string

P478

338

http://www.w3.org/2001/XMLSchema#string

P50

Philip W. Kantoff

Housheng Hansen He

Rodolfo Montironi

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233915352

http://www.w3.org/2001/XMLSchema#string

P698

23239736

http://www.w3.org/2001/XMLSchema#string

P932

3625962

http://www.w3.org/2001/XMLSchema#string